Mexiletine hydrochloride - Arrhythmias

You are here : Home > Formulary Search > Mexiletine hydrochloride - Arrhythmias

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Capsules

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

Restrictions / Comments :

Important

Cardiology specialists only.

Namuscla brand is non-preferred for this indication

Documentation

Evidence Review

Mexilitene for ventricular arrhythmia - Evidence review - August 2019.pdf

PAD Profile

ChemicalSubstance :

Mexiletine hydrochloride

Indication :

Arrhythmias

Group Name :

Keywords :

drug resistant ventricular arrhythmias, sodium channel blockers, ventricular tachycardia

Brand Names Include :

Namuscla

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Mexiletine hydrochloride is used to treat.

Myotonia

Other Drugs

Below are listed other drugs that are used to treat Arrhythmias.

Committee Recommendations (1)

05 Jun 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee approves the prescribing of mexiletine for the management of drug resistant ventricular arrhythmia when initiated and continued by a specialist.

The APC recommend a RED traffic light status for the use of mexiletine for this indication.

All patients currently being prescribed mexiletine in primary care should be referred into a cardiologist for specialist review. Responsibility for prescribing must remain with the specialist.

Patients currently prescribed Namuscla® for the management of drug resistant arrhythmias should be reviewed by specialists to consider switching to the products licensed for ventricular arrhythmias noting that there isn’t an exact equivalent dose.